Balyasny Asset Management LLC Atai Life Sciences N.V. Transaction History
Balyasny Asset Management LLC
- $72.4 Billion
- Q3 2025
A detailed history of Balyasny Asset Management LLC transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 118,874 shares of ATAI stock, worth $475,496. This represents 0.0% of its overall portfolio holdings.
Number of Shares
118,874Holding current value
$475,496% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ATAI
# of Institutions
150Shares Held
45.8MCall Options Held
1.88MPut Options Held
543K-
Ubs Group Ag7.68MShares$30.7 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.43MShares$21.7 Million0.05% of portfolio
-
Morgan Stanley New York, NY4.82MShares$19.3 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.58MShares$10.3 Million0.0% of portfolio
-
Ally Bridge Group (Ny) LLC New York, NY2.29MShares$9.15 Million12.47% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $664M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...